Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.75 |
| ▸ | TERT | O14746 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.67 |
| ▸ | XDH | P47989 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5519499 | 1.00 | SNCA (0.75) | SNCATERTMAPTCXCL12XDH | |
| SCHEMBL25193897 | 0.86 | XDH (0.81) | SNCATERTMAPTCXCL12XDH | |
| SCHEMBL8768036 | 0.86 | XDH (0.81) | SNCATERTMAPTCXCL12XDH | |
| SCHEMBL8768038 | 0.86 | XDH (0.81) | SNCATERTMAPTCXCL12XDH | |
| SCHEMBL31233412 | 0.86 | XDH (0.81) | SNCATERTMAPTCXCL12XDH | |
| SCHEMBL109015 | 0.86 | SNCA (1.00) | SNCATERTMAPTCXCL12XDH | |
| SCHEMBL143710 | 0.86 | SNCA (1.00) | SNCATERTMAPTCXCL12XDH | |
| SCHEMBL9175192 | 0.85 | SNCA (0.73) | SNCATERTMAPTXDH | |
| SCHEMBL9175185 | 0.85 | SNCA (0.73) | SNCATERTMAPTXDH | |
| SCHEMBL6377263 | 0.85 | SNCA (0.73) | SNCATERTMAPTCXCL12XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254658-B1 | REMEDIES FOR THE TREATMENT OF NERVE DIORDERS | TAKARA BIO INC (JP) | 2008-09-24 | — | — | EP | disclosed |
| US-7268160-B2 | Remedies | TAKARA BIO, INC. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20030144316-A1 | Remedies | TAKARA BIO INC. (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1254658-A1 | REMEDIES | TAKARA BIO INC. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144316-A1 | Remedies | NGF, BDNF, NTRK2 | SNCA 408/4885TERT 2273/4885MAPT 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.